Real-time Estimate
Cboe BZX
10:16:08 2024-05-21 am EDT
|
5-day change
|
1st Jan Change
|
13.35
USD
|
0.00%
|
|
+11.66%
|
+11.01%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
79.76
|
127.8
|
253.1
|
410.8
|
822.8
|
1,020
|
-
|
-
|
Enterprise Value (EV)
1 |
42.14
|
74
|
207.5
|
337.4
|
822.8
|
996.9
|
1,119
|
1,246
|
P/E ratio
|
-1.65
x
|
-1.68
x
|
-6.96
x
|
-9.51
x
|
-9.94
x
|
-10.4
x
|
-33.7
x
|
61.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
9.88
x
|
173
x
|
19.7
x
|
25.8
x
|
47.1
x
|
13.6
x
|
5.57
x
|
4.99
x
|
EV / Revenue
|
5.22
x
|
100
x
|
16.1
x
|
21.2
x
|
47.1
x
|
13.3
x
|
6.12
x
|
6.1
x
|
EV / EBITDA
|
-
|
-
|
-
|
-9.61
x
|
-11.6
x
|
-12.5
x
|
23
x
|
-
|
EV / FCF
|
-0.84
x
|
-1.36
x
|
-6.08
x
|
-11.6
x
|
-
|
-15.9
x
|
-135
x
|
33
x
|
FCF Yield
|
-119%
|
-73.4%
|
-16.5%
|
-8.65%
|
-
|
-6.3%
|
-0.74%
|
3.03%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
18,657
|
43,336
|
51,978
|
64,495
|
68,397
|
76,383
|
-
|
-
|
Reference price
2 |
4.275
|
2.950
|
4.870
|
6.370
|
12.03
|
13.35
|
13.35
|
13.35
|
Announcement Date
|
3/11/20
|
3/23/21
|
3/17/22
|
3/16/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
8.072
|
0.7396
|
12.85
|
15.94
|
17.49
|
75.21
|
182.9
|
204.2
|
EBITDA
1 |
-
|
-
|
-
|
-35.12
|
-71.21
|
-79.64
|
48.6
|
-
|
EBIT
1 |
-46.82
|
-59.09
|
-33.8
|
-38.77
|
-73.38
|
-88.68
|
-19.58
|
30.44
|
Operating Margin
|
-580.07%
|
-7,989.01%
|
-262.94%
|
-243.3%
|
-419.62%
|
-117.91%
|
-10.7%
|
14.9%
|
Earnings before Tax (EBT)
1 |
-47.58
|
-59.76
|
-34.58
|
-41.02
|
-78.5
|
-84.57
|
-11.18
|
28.55
|
Net income
1 |
-47.58
|
-59.76
|
-34.58
|
-41.02
|
-78.5
|
-97.39
|
-30.28
|
18.82
|
Net margin
|
-589.48%
|
-8,080.09%
|
-269.02%
|
-257.39%
|
-448.89%
|
-129.5%
|
-16.56%
|
9.22%
|
EPS
2 |
-2.590
|
-1.760
|
-0.7000
|
-0.6700
|
-1.210
|
-1.289
|
-0.3957
|
0.2175
|
Free Cash Flow
1 |
-50.13
|
-54.33
|
-34.14
|
-29.18
|
-
|
-62.83
|
-8.263
|
37.72
|
FCF margin
|
-621.06%
|
-7,345.59%
|
-265.63%
|
-183.12%
|
-
|
-83.54%
|
-4.52%
|
18.47%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
200.35%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/23/21
|
3/17/22
|
3/16/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
3.215
|
3.492
|
3.918
|
3.165
|
5.36
|
4.493
|
4.786
|
3.678
|
4.531
|
2.972
|
9.8
|
18.03
|
30.17
|
38.16
|
48.54
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-3.416
|
-
|
-
|
-
|
-
|
-
|
-29
|
-15
|
-7.341
|
-
|
-
|
EBIT
1 |
-11.36
|
-14.47
|
-8.97
|
-12
|
-6.497
|
-9.232
|
-22.82
|
-14.89
|
-26.44
|
-28.8
|
-24.24
|
-22.19
|
-15.28
|
-4.843
|
2.789
|
Operating Margin
|
-353.42%
|
-414.43%
|
-228.94%
|
-379.02%
|
-121.21%
|
-205.48%
|
-476.91%
|
-404.87%
|
-583.45%
|
-969.08%
|
-247.37%
|
-123.08%
|
-50.65%
|
-12.69%
|
5.75%
|
Earnings before Tax (EBT)
1 |
-11.56
|
-15.94
|
-9.447
|
-9.092
|
-6.533
|
-11.74
|
-23.52
|
-15.79
|
-27.45
|
-40.93
|
-22.53
|
-19.94
|
-9.668
|
-7.143
|
0.489
|
Net income
1 |
-11.56
|
-15.94
|
-9.447
|
-9.092
|
-6.533
|
-11.74
|
-23.52
|
-15.79
|
-27.45
|
-40.93
|
-25.07
|
-23.56
|
-16.22
|
-7.143
|
0.489
|
Net margin
|
-359.66%
|
-456.56%
|
-241.12%
|
-287.27%
|
-121.88%
|
-261.41%
|
-491.37%
|
-429.31%
|
-605.83%
|
-1,377.12%
|
-255.78%
|
-130.7%
|
-53.78%
|
-18.72%
|
1.01%
|
EPS
2 |
-0.2300
|
-0.3000
|
-0.1500
|
-0.1400
|
-0.0900
|
-0.1800
|
-0.3600
|
-0.2400
|
-0.4200
|
-0.5400
|
-0.3286
|
-0.3057
|
-0.2129
|
-0.0900
|
0.0100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/22
|
5/12/22
|
8/11/22
|
11/8/22
|
3/16/23
|
5/4/23
|
8/10/23
|
11/7/23
|
3/13/24
|
5/13/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
99.5
|
227
|
Net Cash position
1 |
37.6
|
53.8
|
45.6
|
73.4
|
-
|
22.8
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
2.048
x
|
-
|
Free Cash Flow
1 |
-50.1
|
-54.3
|
-34.1
|
-29.2
|
-
|
-62.8
|
-8.26
|
37.7
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-51.4%
|
-
|
-110%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-0.4700
|
-
|
-1.080
|
0.0500
|
-
|
Capex
1 |
1.85
|
0.75
|
0.11
|
0.59
|
-
|
1.42
|
1.43
|
1.45
|
Capex / Sales
|
22.92%
|
101.68%
|
0.83%
|
3.72%
|
-
|
1.88%
|
0.78%
|
0.71%
|
Announcement Date
|
3/11/20
|
3/23/21
|
3/17/22
|
3/16/23
|
3/13/24
|
-
|
-
|
-
|
Last Close Price
13.35
USD Average target price
24.14
USD Spread / Average Target +80.85% Consensus |
1st Jan change
|
Capi.
|
---|
| +11.01% | 1.02B | | +38.96% | 705B | | +32.57% | 583B | | -3.06% | 364B | | +21.34% | 332B | | +6.05% | 291B | | +16.21% | 238B | | -3.56% | 210B | | +10.52% | 209B | | +9.38% | 169B |
Other Pharmaceuticals
|